Evidence map›Paper›PMID 35113455›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2022

Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination.

Zhuofan Li, Ki-Hye Kim, Noopur Bhatnagar, Bo Ryoung Park, Subbiah Jeeva, Yu-Jin Jung, Jannatul Raha, Sang-Moo Kang, Xinyuan Chen

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Proteomic Analysis of Influenza.Advances in experimental medicine and biology · 2026
    Review
  2. Dual roles ofFrontiers in immunology · 2025
    Article
  3. Emerging adjuvants for intradermal vaccination.International journal of pharmaceutics · 2023
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhuofan LiBiomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
Ki-Hye KimCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Noopur BhatnagarCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Bo Ryoung ParkCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Subbiah JeevaCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Yu-Jin JungCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Jannatul RahaCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Sang-Moo KangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Xinyuan ChenBiomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.ORCID https://orcid.org/0000-0003-4735-3922
Georgia State University · USUniversity of Rhode Island · US

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
Seasonal and universal Vaccination in aged populations with pre-existing immunityR01AI154656 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2021 to 2025
$2.7M
Novel adjuvant to boost humoral and cellular immune responses against influenzaR01AI139473 · NIAID · UNIVERSITY OF RHODE ISLAND · PI CHEN, XINYUAN · 2018 to 2022
$2.1M
High-density flagellin-displayed virus-like particle for universal influenza vaccine development'R21AI156510 · NIAID · UNIVERSITY OF RHODE ISLAND · PI CHEN, XINYUAN · 2021 to 2022
$433k
Multi NA-based influenza vaccinesR41AI152800 · NIAID · ADVAC, LLC · PI KANG, SANG-MOO · 2020 to 2020
$272k
NIAID NIH HHS R01 AI093772NIAID NIH HHS R01 AI139473NIAID NIH HHS R01 AI154656NIAID NIH HHS R21 AI156510NIAID NIH HHS R41 AI152800
6 · The paper itself

Abstract

Pre-pandemic influenza H5N1 vaccine has relatively low immunogenicity and often requires high antigen amounts and two immunizations to induce protective immunity. Incorporation of vaccine adjuvants is promising to stretch vaccine doses during pandemic outbreaks. This study presents a physical radiofrequency (RF) adjuvant (RFA) to conveniently and effectively increase the immunogenicity and efficacy of H5N1 vaccine without modification of vaccine preparation. Physical RFA is based on a brief RF treatment of the skin to induce thermal stress to enhance intradermal vaccine-induced immune responses with minimal local or systemic adverse reactions. We found that physical RFA could significantly increase H5N1 vaccine-induced hemagglutination inhibition antibody titers in murine models. Intradermal H5N1 vaccine in the presence of RFA but not vaccine alone significantly lowered lung viral titers, reduced body weight loss, and improved survival rates after lethal viral challenges. The improved protection in the presence of RFA was correlated with enhanced humoral and cellular immune responses to H5N1 vaccination in both male and female mice, indicating no gender difference of RFA effects in murine models. Our data support further development of the physical RFA to conveniently enhance the efficacy of H5N1 vaccine.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralFemaleHemagglutination Inhibition TestsImmunity, CellularImmunity, HumoralInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesLungMaleMiceMice, Inbred C57BLOrthomyxoviridae InfectionsPandemicsVaccinationAdjuvants, ImmunologicAntibodies, ViralInfluenza VaccinesH5N1MF59physical adjuvantradiofrequencyRFA

Identifiers

PMID35113455
PMCPMC8928172
OpenAlexW4210650714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.